Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.

ABSTRACT:

Importance

Patients with osteoarthritis (OA) may remain symptomatic with traditional OA treatments.

Objective

To assess 2 subcutaneous tanezumab dosing regimens for OA.

Design, setting, and participants

A randomized, double-blind, multicenter trial from January 2016 to May 14, 2018 (last patient visit). Patients enrolled were 18 years or older with hip or knee OA, inadequate response to OA analgesics, and no radiographic evidence of prespecified joint safety conditions.

Interventions

Patients received by subcutaneous administration either tanezumab, 2.5 mg, at day 1 and week 8 (n = 231); tanezumab, 2.5 mg at day 1 and 5 mg at week 8 (ie, tanezumab, 2.5/5 mg; n = 233); or placebo at day 1 and week 8 (n = 232).

Main outcomes and measures

Co-primary end poi

SUBMITTER: Schnitzer TJ 

PROVIDER: S-EPMC6613301 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature